Cytomegalovirus infection secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Secondary prophylaxis of CMV infection includes preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA. | Secondary prophylaxis of [[Cytomegalovirus infection|CMV infection]] includes preemptive treatment with [[Antiviral drug|antiviral agents]] in asymptomatic patients with positive blood [[PCR]] for [[CMV]] [[DNA]]. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
*Secondary prevention of CMV infection includes preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.<ref name="pmid27772620">{{cite journal| author=Santos CA| title=Cytomegalovirus and Other β-Herpesviruses. | journal=Semin Nephrol | year= 2016 | volume= 36 | issue= 5 | pages= 351-361 | pmid=27772620 | doi=10.1016/j.semnephrol.2016.05.012 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27772620 }} </ref><ref name="pmid27340928">{{cite journal| author=Potena L, Solidoro P, Patrucco F, Borgese L| title=Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update. | journal=Expert Opin Pharmacother | year= 2016 | volume= 17 | issue= 12 | pages= 1611-22 | pmid=27340928 | doi=10.1080/14656566.2016.1199684 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27340928 }} </ref><ref name="Kotton2013">{{cite journal|last1=Kotton|first1=C. N.|title=CMV: Prevention, Diagnosis and Therapy|journal=American Journal of Transplantation|volume=13|issue=s3|year=2013|pages=24–40|issn=16006135|doi=10.1111/ajt.12006}}</ref> | *Secondary prevention of [[CMV infection]] includes preemptive treatment with [[Antiviral drugs|antiviral agents]] in asymptomatic patients with positive blood [[PCR]] for [[CMV]] [[DNA]].<ref name="pmid27772620">{{cite journal| author=Santos CA| title=Cytomegalovirus and Other β-Herpesviruses. | journal=Semin Nephrol | year= 2016 | volume= 36 | issue= 5 | pages= 351-361 | pmid=27772620 | doi=10.1016/j.semnephrol.2016.05.012 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27772620 }} </ref><ref name="pmid27340928">{{cite journal| author=Potena L, Solidoro P, Patrucco F, Borgese L| title=Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update. | journal=Expert Opin Pharmacother | year= 2016 | volume= 17 | issue= 12 | pages= 1611-22 | pmid=27340928 | doi=10.1080/14656566.2016.1199684 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27340928 }} </ref><ref name="Kotton2013">{{cite journal|last1=Kotton|first1=C. N.|title=CMV: Prevention, Diagnosis and Therapy|journal=American Journal of Transplantation|volume=13|issue=s3|year=2013|pages=24–40|issn=16006135|doi=10.1111/ajt.12006}}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 19:51, 30 May 2017
|
Cytomegalovirus infection Microchapters |
|
Differentiating Cytomegalovirus infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cytomegalovirus infection secondary prevention On the Web |
|
American Roentgen Ray Society Images of Cytomegalovirus infection secondary prevention |
|
Risk calculators and risk factors for Cytomegalovirus infection secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Kuchkuntla, M.B.B.S[2]
Overview
Secondary prophylaxis of CMV infection includes preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.
Secondary Prevention
- Secondary prevention of CMV infection includes preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.[1][2][3]
References
- ↑ Santos CA (2016). "Cytomegalovirus and Other β-Herpesviruses". Semin Nephrol. 36 (5): 351–361. doi:10.1016/j.semnephrol.2016.05.012. PMID 27772620.
- ↑ Potena L, Solidoro P, Patrucco F, Borgese L (2016). "Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update". Expert Opin Pharmacother. 17 (12): 1611–22. doi:10.1080/14656566.2016.1199684. PMID 27340928.
- ↑ Kotton, C. N. (2013). "CMV: Prevention, Diagnosis and Therapy". American Journal of Transplantation. 13 (s3): 24–40. doi:10.1111/ajt.12006. ISSN 1600-6135.